Esperion Therapeutics, Inc.

NASDAQ:ESPR

Biotechnology

Healthcare
$3.18 -0.32%

+$0.00 today

Market cap
$661.15M
Beta
1.07
P/E (TTM)
-107.3
EPS (TTM)
-$0.03
52W Low $0.95High $4.18

Volume 0.00M

Average 12.29M

ESPR Income Before Tax

Profit after all operating and non-operating items but before income tax.

Esperion Therapeutics, Inc.NASDAQ: ESPR

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$25.2M, compared with -$40.46M a year earlier. Trailing-twelve-month income before tax was -$5.58M.

Context

  • Income before tax amounted to 5.2% of revenue in FY2025, down 10.4 pp from a year earlier.
  • Income before tax grew in size in 0 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$25.2M or moves back toward the trailing-twelve-month quarterly average of -$1.4M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$25.2M-139.6% QoQ
Last fiscal yearDec 2025
-$20.84M+59.7% YoY
LTMMar 2026
-$5.58M+96.4% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+37.7%——
1 year+59.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(20.84M) USD
Year-over-year change
+59.7%

Income Before Tax vs competitors

How ESPR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +96.4% is the 2nd highest of 10, against a peer median of -10.2%.
  • Income before tax amounts to 1.3% of revenue for ESPR, versus a peer median of 28.7%.
ESPR Competitors
Income Before Tax for ESPR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
SIGASIGA Technologies, Inc.LTM Mar 2026$26.93M USD-56.8%-11.7%28.7%
EBSEmergent BioSolutions Inc.LTM Mar 2026$3.5M USD+105.6%—0.5%
ESPREsperion Therapeutics, Inc.LTM Mar 2026-$5.58M USD+96.4%—1.3%
SNDLSNDL Inc.LTM Mar 2026-CA$12.48M CAD+88.9%—1.3%
CRVSCorvus Pharmaceuticals, Inc.LTM Mar 2026-$44.17M USD-6.7%——
OFIXOrthofix Medical Inc.LTM Mar 2026-$59.51M USD+57.7%—7.2%
AQSTAquestive Therapeutics, Inc.LTM Mar 2026-$68.91M USD-27.0%—137.1%
ABSIAbsci CorporationLTM Mar 2026-$118.35M USD-10.2%—6445.8%
OLMAOlema Pharmaceuticals, Inc.LTM Mar 2026-$185.15M USD-43.6%——
RGNXREGENXBIO Inc.LTM Mar 2026-$290.01M USD-83.9%—330.2%
Peer median (excluding ESPR) —-10.2%-11.7%28.7%

Competitors are the stored peer set for ESPR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue78.45M75.48M116.33M332.31M403.14M
Cost of Revenue14.22M26.97M43.27M68.6M129.22M
Gross Profit64.23M48.51M73.07M263.71M273.91M
Gross Margin81.9%64.3%62.8%79.4%67.9%
Research & Development105.98M118.93M86.11M46.24M47.85M
Selling, General & Admin184.99M109.08M142.52M163.07M165.79M
Operating Expenses290.96M228.01M228.63M209.31M213.64M
Depreciation & Amortization612K500K164K63K105K
EBITDA(222.14M)(176.35M)(150.11M)7.57M63.87M
EBITDA Margin-283.2%-233.7%-129.0%2.3%15.8%
Operating Income(226.73M)(179.5M)(155.56M)54.4M60.27M
Operating Margin-289.0%-237.8%-133.7%16.4%15.0%
Interest Income00003.5M
Interest Expense46.35M56.81M58.98M59.25M84.6M
Other Income / Expenses(42.38M)(54.16M)(53.69M)(106.15M)(81.11M)
Income Before Tax(269.11M)(233.66M)(209.25M)(51.75M)(20.84M)
Pre-Tax Margin-343.0%-309.6%-179.9%-15.6%-5.2%
Income Tax Expense00001.84M
Net Income(269.11M)(233.66M)(209.25M)(51.75M)(22.68M)
Net Margin-343.0%-309.6%-179.9%-15.6%-5.6%
EPS (Basic)(11.03)(4.33)(2.03)(0.28)(0.11)
EPS (Diluted)(11.03)(4.33)(2.03)(0.28)(0.11)
Weighted Avg Shares28.9M66.41M103.11M187.18M207.87M
Weighted Avg Shares (Diluted)28.9M66.41M103.11M187.18M207.87M

Esperion Therapeutics, Inc.

NASDAQ:ESPR

Intrinsic Alpha fair value

Locked

Current Price

$3.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.